You are here

hemophilia

BioMarin preaches patience amid slow sales for hemophilia gene therapy

BioPharma Dive

Fri, 02/23/24 - 10:26 am

BioMarin secures hemophilia gene therapy coverage in Germany

BioPharma Dive

Wed, 11/29/23 - 11:35 pm

Roche scores—again—in hemophilia drug patent case against Takeda

Fierce Pharma

Thu, 09/21/23 - 11:47 am

Novo Nordisk's phase 3 data for hemophilia hopeful fail to shake off Pfizer's shadow

Fierce Biotech

Tue, 06/27/23 - 10:36 pm

clinical trials

Pfizer's hemophilia drug hits in phase 3, giving it a chance to leapfrog Novo Nordisk

Fierce Biotech

Tue, 05/30/23 - 10:07 am

clinical trials

BioMarin's hemophilia gene therapy faces further delays over fresh FDA requests

Fierce Biotech

Tue, 11/8/22 - 10:46 am

Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies

Fierce Pharma

Thu, 11/3/22 - 11:02 am

ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag

BioSpace

Thu, 09/15/22 - 10:14 am

Freeline's One Dose Gene Therapy could Transform Hemophilia B Treatment

BioSpace

Sun, 07/24/22 - 07:56 pm

clinical trials

Freeline Therapeutics

Novo Nordisk A/S: Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors

Yahoo Finance

Sun, 07/10/22 - 11:51 pm

Fresh data show UniQure's hemophilia gene therapy appears to hold up

BioPharma Dive

Fri, 12/10/21 - 12:01 am

Pfizer tears up gene therapy timelines, revealing a series of phase 3 delays that end vision of a banner 2022

Fierce Biotech

Wed, 11/3/21 - 10:43 am

Duchenne Muscular Dystrophy

Sangamo Therapeutics

Takeda's Baxalta settles with Bayer over $173M hemophilia patent infringement verdict

Fierce Pharma

Wed, 05/19/21 - 11:05 pm

FDA lifts clinical hold on uniQure's gene therapy amid cancer concerns; shares jump

Fierce Biotech

Mon, 04/26/21 - 12:06 pm

Sanofi revises fitusiran dosing to cut risk of thrombotic events in hemophilia phase 3

Fierce Biotech

Mon, 02/8/21 - 10:41 am

Gene therapy for hemophilia: So close, yet so far away

BioPharma Dive

Thu, 01/28/21 - 11:18 pm

Novo invests in Hemab, a company going against the hemophilia gene therapy grain with a plan for bispecifics

Endpoints

Mon, 12/14/20 - 10:53 am

Sanofi accepts a lengthy delay as its hemophilia drug fitusiran resumes a PhIII after safety fears forced a halt

Endpoints

Thu, 12/10/20 - 07:20 pm

Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy

Pharmaceutical Business Review

Tue, 11/24/20 - 10:23 am

clinical trials

Sanofi/Alnylam’s haemophilia drug hits another safety speed-bump

Pharmaforum

Mon, 11/9/20 - 10:59 am

Pages